Sorafenib use for recurrent hepatocellular cancer after resection or transplantation: Observations from a US regional analysis of the GIDEON registry

Robert C G Martin, Elizabeth Bruenderman, Allen Cohn, Bilal Piperdi, Rebecca Miksad, Jean Francois Geschwind, Alec Goldenberg, Arun Sanyal, Ellen Zigmont, Svetlana Babajanyan, Pamela Foreman, Parvez Mantry, Brendan McGuire, Pierre Gholam

Research output: Contribution to journalArticle

8 Scopus citations

Abstract

Treatment of unresectable recurrent hepatocellular carcinoma (HCC) in patients who recur after resection or orthotopic liver transplantation (OLT) remains a clinical challenge. One option is sorafenib, although little is known about its safety and tolerance in this unique patient population; therefore, we analyzed patients who underwent prior surgical resection and/or OLT and were treated with sorafenib in US cohort of GIDEON registry. In US, 645 patients were enrolled; 553 for intent to treat and 563 for safety. Data were analyzed in the safety population of 479 patients no surgery and 56 for resection or OLT. Forty-one patients underwent resection prior to the initiation of sorafenib, 15 patients had previously received an OLT, and 6 patients had both resection and OLT. Initial low starting doses (400 mg/day) were observed for more patients with prior OLT (71%) than prior resection (36%), resection and OLT (50%), concomitant OLT (25%), and no surgery (36%). Most AEs occurred in the first 4 weeks of treatment. Drug-related AEs were higher in patients with prior resection (87%), prior OLT (100%), or both (100%) than in patients with concomitant OLT (63%) or no surgery (70%). However, incidence of AEs resulting in permanent discontinuation were similar in all groups (19–38%).

Original languageEnglish (US)
Pages (from-to)688-695
Number of pages8
JournalAmerican Journal of Surgery
Volume213
Issue number4
DOIs
StatePublished - Apr 1 2017

    Fingerprint

Keywords

  • Hepatocellular cancer
  • Liver
  • Recurrence
  • Resection
  • Sorafenib
  • Transplantation
  • Treatment of recurrent cancer

ASJC Scopus subject areas

  • Surgery

Cite this

Martin, R. C. G., Bruenderman, E., Cohn, A., Piperdi, B., Miksad, R., Geschwind, J. F., Goldenberg, A., Sanyal, A., Zigmont, E., Babajanyan, S., Foreman, P., Mantry, P., McGuire, B., & Gholam, P. (2017). Sorafenib use for recurrent hepatocellular cancer after resection or transplantation: Observations from a US regional analysis of the GIDEON registry. American Journal of Surgery, 213(4), 688-695. https://doi.org/10.1016/j.amjsurg.2016.10.006